Evidence map›Paper›PMID 34076753›Full record

Trial reportWorld journal of urology2021

Patrick Bowden, Andrew W See, Kevin So, Nathan Lawrentschuk, Daniel Moon, Declan G Murphy, Ranjit Rao, Alan Crosthwaite, Dennis King, Hodo Haxhimolla and 10 more

Open access · hybridAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in World journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Why does PSMA PET improve quality of life?European journal of nuclear medicine and molecular imaging · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 9 institutions in 2 countries.

Patrick BowdenIcon Cancer Centre, Richmond, VIC, Australia. pat.bowden@icon.team.ORCID http://orcid.org/0000-0002-5085-3322
Andrew W SeeIcon Cancer Centre, Richmond, VIC, Australia.
Kevin SoIcon Cancer Centre, Richmond, VIC, Australia.
Nathan LawrentschukDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Daniel MoonRoyal Melbourne Clinical School, University of Melbourne, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-8863-9727
Declan G MurphyDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-7500-5899
Ranjit RaoEpworth HealthCare, Richmond, VIC, Australia.
Alan CrosthwaiteEpworth Eastern, Box Hill, VIC, Australia.
Dennis KingCabrini Hospital, Malvern, VIC, Australia.
Hodo HaxhimollaDepartment of Urology, The Canberra Hospital, Garran, ACT, Australia.
Jeremy GrummetEpworth HealthCare, Richmond, VIC, Australia.
Paul RuljancichEpworth Eastern, Box Hill, VIC, Australia.
Dennis GyomberDepartment of Surgery, University of Melbourne, Heidelberg, VIC, Australia.
Adam LandauEpworth HealthCare, Richmond, VIC, Australia.
Nicholas CampbellEpworth Eastern, Box Hill, VIC, Australia.
Mark FrydenbergDepartment of Surgery, Monash University, Clayton, VIC, Australia.
Lloyd M L SmythIcon Cancer Centre, Richmond, VIC, Australia.ORCID http://orcid.org/0000-0002-6675-5807
Skye NolanIcon Cancer Centre, Richmond, VIC, Australia.
Stella M GwiniSchool of Public Health and Preventive Medicine, Monash University, Clayton, VIC, Australia.ORCID http://orcid.org/0000-0002-0295-4575
Dean P McKenzieEpworth HealthCare, Richmond, VIC, Australia.ORCID http://orcid.org/0000-0002-0006-9062
Epworth Hospital · AUMonash University · AUThe Royal Melbourne Hospital · AUCabrini Hospital · AUCanberra Hospital · AUIcon (Australia) · AUPeter MacCallum Cancer Centre · AUProstate Cancer Foundation of Australia · AUThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate outcomes for men with biochemically recurrent prostate cancer who were selected for transponder-guided salvage radiotherapy (SRT) to the prostate bed alone by

methodsThis is a single-arm, prospective study of men with a prostate-specific antigen (PSA) level rising to 0.1-2.5 ng/mL following radical prostatectomy. Patients were staged with

resultsNinety-two patients (median PSA of 0.18 ng/ml, IQR 0.12-0.36), were screened with

conclusionPre-SRT TRIAL REGISTRATION NUMBER: ACTRN12615001183572, 03/11/2015, retrospectively registered.

Indexed as

Gallium IsotopesGallium RadioisotopesRadiopharmaceuticalsAgedHumansMaleMiddle AgedNeoplasm Recurrence, LocalPositron-Emission TomographyProspective StudiesProstatectomyProstate-Specific AntigenProstatic NeoplasmsSalvage TherapyTreatment Outcomegallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesProstate-Specific AntigenRadiopharmaceuticalsBiochemical recurrenceImagingPositron emission tomographyProstate cancerProstate-specific membrane antigenRadiotherapy

Identifiers

PMID34076753
PMCPMC8571130
OpenAlexW3164858635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.